Evidence map›Paper›PMID 31824933›Full record

ArticleFrontiers in bioengineering and biotechnology2019

Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability.

Liang Feng, Zhi-Yong Li, Long Wang, Xing-Hua Li, Ya-Ping Chen, Bing Yang, Dang Yang, Yuan-Pei Lian, Xue-Feng Hou, Jun-Hui Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Liang FengSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Zhi-Yong LiChina Minority Traditional Medical Center, Minzu University of China, Beijing, China.
Long WangSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Xing-Hua LiSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Ya-Ping ChenSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Bing YangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Dang YangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Yuan-Pei LianSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Xue-Feng HouSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Jun-Hui LiDepartment of Nephrology, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai, China.
Shu-Min DingSchool of Pharmaceutical Engineering & Life Science, Changzhou University, Changzhou, China.
Xiao-Bin JiaSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CNNanjing University of Chinese Medicine · CNChangzhou University · CNMinzu University of China · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wedelolactone (WED) is commonly used for the treatment of doxorubicin (DOX)-induced kidney damage, but its efficacy is limited by its poor solubility and bioavailability. In this study, we developed a novel delivery system of WED-loaded micelles (WED-M) with Solutol

Indexed as

micellesnephrotoxicityoxidative stresspodocyteswedelolactone

Identifiers

PMID31824933
PMCPMC6883003
OpenAlexW2991118132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.